Comparison of CD20 expression in B-cell lymphoma between newly diagnosed, untreated cases and those after rituximab treatment

Cancer Science

Volumn 103, Issue 8, 2012, Pages 1567-1573

  Miyoshi, Hiroaki ^a   Arakawa, Fumiko ^a   Sato, Kensaku ^a   Kimura, Yoshizo ^a   Kiyasu, Junichi ^a   Takeuchi, Masanori ^a   Yoshida, Maki ^a   Ichikawa, Ayako ^a   Ishibashi, Yukinao ^a   Nakamura, Yukihiko ^a   Nakashima, Shinji ^a   Niino, Daisuke ^a   Sugita, Yasuo ^a   Ohshima, Koichi ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; PIRARUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; CLINICAL ARTICLE; EXON; FEMALE; FLOW CYTOMETRY; FOLLICULAR LYMPHOMA; GENE MUTATION; GENE SEQUENCE; HUMAN; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT RESPONSE; TUMOR BIOPSY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA, FOLLICULAR; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; SEQUENCE ANALYSIS; YOUNG ADULT;

EID: 84864307317     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2012.02307.x     Document Type: Article

References (21)

1. Maloney DG, Liles TM, Czerwinski DK et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 1994; 84: 2457-66.
2. Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. New Engl J Med 2002; 346: 235-42.
3. Habermann TM, Weller EA, Morrison VA et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006; 24: 3121-7.
4. Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 2003; 22: 7359-68.
5. Golay F, Lazzari M, Facchinetti V et al. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood 2001; 98: 3383-9.
6. Czuczman MS, Olejniczak S, Gowda A et al. Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels. Clin Cancer Res 2008; 14: 1561-70.
7. Johnson NA, Boyle M, Bashashati A et al. Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival. Blood 2009; 113: 3773-80.
8. Takei K, Yamazaki T, Sawada U et al. Analysis of changes in CD20, CD55, and CD59 expression on established rituximab-resistant B-lymphoma cell lines. Leukemia Res 2006; 30: 625-31.
9. D'Auria F, Guariglia R, Villani O et al. Modulation of CD20 antigen expression after rituximab treatment: a retrospective study in patients with chronic lymphocytic leukemia. Clin Ther 2010; 32: 1911-6.
10. Hiraga J, Tomita A, Sugimoto T et al. Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance. Blood 2009; 113: 4885-93.
11. Terui Y, Mashima Y, Sugimura N et al. Identification of CD20 C-Terminal deletion mutations associated with loss of CD20 expression in non-Hodgkin's lymphoma. Clin Cancer Res 2009; 15: 2523-30.
12. Karube K, Aoki R, Nomura Y et al. Usefulness of flow cytometry for differential diagnosis of precursor and peripheral T-cell and NK-cell lymphomas: Analysis of 490 cases. Patho Int 2008; 58: 89-97.
13. Hans CP, Weisenburger DD, Greiner TC et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Br J Haematol 2004; 144: 716-25.
14. Michels J, Foria V, Mead B et al. Immunohistochemical analysis of the antiapoptotic Mcl-1 and Bcl-2 proteins in follicular lymphoma. Br J Haematol 2006; 132: 743-6.
15. Zhao WL, Daneshpouy ME, Mounier N et al. Prognostic significance of bcl-xL gene expression and apoptotic cell counts in follicular lymphoma. Blood 2004; 103: 695-7.
16. Miyagi AM, Taniguchi H, Nomoto J et al. Histological and immunophenotypic changes in 59 cases of B-cell non-Hodgkin's lymphoma after rituximab therapy. Cancer Sci 2009; 100: 54-61.
17. Binder M, Otto F, Mertelsmann R et al. The epitope recognized by rituximab. Blood 2006; 108: 1975-8.
18. Johnson NA, Leach S, Woolcock B et al. CD20 mutations involving the rituximab epitope are rare in diffuse large B-cell lymphomas and are not a significant cause of R-CHOP failure. Haematologica 2009; 94: 423-7.
19. Polyak MJ, Deans JP. Alanine-170 and proline-172 are critical determinants for extracellular CD20 epitopes; heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quaternary structure. Blood 2002; 99: 3256-62.
20. Mason DY, Comans-Bitter WM, Cordell JL et al. Antibody L26 recognizes an intracellular epitope on the B-cell-associated CD20 antigen. Am J Pathol 1990; 136: 1215-22.
21. Tomita A, Hiraga J, Kiyoi H et al. Epigenetic regulation of CD20 protein expression in a novel B-cell lymphoma cell line, RRBL1, established from a patient treated repeatedly with rituximab-containing chemotherapy. Int J Hematol 2007; 85: 49-57.